



Notice of Nexstim Plc's Half-Year Report H1 2026

Press release, Helsinki, 11 August 2026 at 9 AM (EEST)

Nexstim Plc ("**Nexstim**" or "**Company**") will publish its half-yearly report for the six months ended 30 June 2026 on Friday 14 August 2026 at approximately 9:00 am Finnish time.

The company will hold two live webinars for media, investors, and analysts on Friday 14 August 2026. CEO Mikko Karvinen and CFO Joonas Juoksolahti will present the financial and operational results followed by a Q&A session.

The first live webinar will be in Finnish, and it takes place at 10:30 am EEST. The second live webinar will be in English at 3 pm EEST.

Webinar details:

To attend the webinars, please register via links below.

Webinar in Finnish on August 14, 2026, at 10:30 am (EEST): [Sign up here>>](#)

Webinar in English on August 14, 2026, at 3 pm (EEST): [Sign up here>>](#)

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com.